再鼎医药(09688)今日盘中大涨7.3%，引发市场广泛关注。
消息面上，再鼎医药在第44届摩根大通医疗健康大会上介绍了2026年战略重点及临床开发进展。其中，Zocilurtatug pelitecan(Zoci)有望成为公司肿瘤领域首款全球上市产品，计划在2026年底前启动三项注册性关键研究，包括二线及以上小细胞肺癌、一线小细胞肺癌和神经内分泌癌。
此外，再鼎医药在中国拥有八款商业化产品，形成了多元化且可持续的商业化管线组合。呫诺美林曲司氯铵胶囊预计于2026年上半年上市，其他产品如povetacicept和elegrobart(VRDN-003)也将进一步推动业务增长。这些进展增强了投资者对公司未来业绩的乐观预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.